Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy, presents the collation of chapters written by eminent scientists worldwide. CRISPR-Cas9 is a key technology for targeted genome editing and regulation in a number of organisms including mammalian cells. It is a rapid, simple, and cost-effective solution. CRISPR-Cas system has recently gained much scientific and public attention. This volume covers CRISPR-Cas9 based mammalian genome editing, creating disease models, cancer therapy, neurological, heredity, blood disorders, defective gene correction, stem cells therapy, epigenetic modifications, patents, ethics, biosafety and regulatory issues challenges and opportunities. This book is a key source of information on mammalian genome editing available in a single volume. This book will be useful for beginners in mammalian genome editing and also students, researchers, scientists, policymakers, clinicians and stakeholders interested in genome editing in several areas.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1. An introduction to CRISPR-Cas systems for reprogramming of the genome of mammalian cells 2. CRISPR-Cas systems for genome editing of mammalian cells 3. Genome-wide detection and analysis of CRISPR-Cas off-targets 4. CRISPR-based diagnostics for detection of pathogens 5. Creating cell lines for mimicking diseases 6. Modulating Cas9 activity for precision gene editing 7. Crispr-Cas9 in cancer therapeutics 8. CRISPR-Cas9 for treating heredity diseases 9. CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals 10. Recent advances in stem cells & gene editing: Drug discovery and therapeutics 11. Genome editing of hPSCs: Recent progress in hPSC-based disease modeling for understanding disease mechanisms 12. Genome editing in cardiovascular diseases 13. CRISPR/Cas9 in epigenetics studies of health and disease 14. Patents, ethics, biosafety and regulation using CRISPR technology
